Harrison Stephanie L, Lane Deirdre A, Buckley Benjamin J R, Chatterjee Kausik, Alobaida Muath, Shipley Emily, Lip Gregory Y H
Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK.
Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Vasc Health Risk Manag. 2022 Apr 26;18:313-318. doi: 10.2147/VHRM.S357829. eCollection 2022.
Further research is needed to refine risk prediction models for adverse cardiovascular outcomes following stroke in contemporary clinical practice, such as incident atrial fibrillation (AF), recurrent stroke, and cognitive impairment and dementia. The aims of this study are to prospectively investigate cardiovascular outcomes and risk factors for incident cardiovascular disease in a post-stroke cohort, and to externally validate, refine and expand current risk prediction models for cardiovascular and cardiovascular-related outcomes. The study sample size was based on the development of post-stroke risk prediction models for AF and was calculated as 1222 participants. The study design is a multicentre, prospective, observational cohort study. Participants will be adult patients admitted for ischaemic stroke confirmed by stroke physician or transient ischaemic attack (TIA) confirmed by MRI. Routinely collected data will be used in addition to the completion of simple validated questionnaires by the participants. Follow-up will be undertaken 12-months from the date of admission to hospital, in addition to linkage to routinely collected follow-up hospitalisation and mortality data. The primary outcomes are cardiovascular outcomes (including incident AF, stroke, TIA and myocardial infarction) at 12-month follow-up, all-cause mortality and mortality from cardiovascular causes, and incident cognitive impairment and dementia. Secondary outcomes include changes in function, depression, anxiety, fatigue and quality of life. The study has received approval from the Health Research Authority Research Ethics Committee (21/WA/0209), and is registered on https://www.clinicaltrials.gov/ (Identifier NCT05132465). Recruitment for the study began in October 2021 with completion of recruitment at all participating centres anticipated by October 2022.
在当代临床实践中,需要进一步开展研究来完善中风后不良心血管结局的风险预测模型,如新发房颤(AF)、复发性中风、认知障碍和痴呆。本研究的目的是前瞻性调查中风后队列中心血管结局及心血管疾病的危险因素,并对当前心血管及心血管相关结局的风险预测模型进行外部验证、完善和扩展。研究样本量基于中风后房颤风险预测模型的开发确定,计算得出为1222名参与者。研究设计为多中心、前瞻性、观察性队列研究。参与者将为经中风医生确诊的缺血性中风成年患者或经MRI确诊的短暂性脑缺血发作(TIA)患者。除参与者完成简单的经过验证的问卷外,还将使用常规收集的数据。随访将在入院日期起12个月时进行,此外还将与常规收集的随访住院和死亡数据进行关联。主要结局为12个月随访时的心血管结局(包括新发房颤、中风、TIA和心肌梗死)、全因死亡率和心血管原因死亡率,以及新发认知障碍和痴呆。次要结局包括功能、抑郁、焦虑、疲劳和生活质量的变化。该研究已获得健康研究管理局研究伦理委员会的批准(21/WA/0209),并在https://www.clinicaltrials.gov/上注册(标识符NCT05132465)。该研究于2021年10月开始招募,预计所有参与中心将于2022年10月完成招募。